Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Basic) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EPS (Basic) for 15 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 85.01% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.21 through Dec 2025, up 41.26% year-over-year, with the annual reading at -$0.29 for FY2025, 85.13% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.07 at Plus Therapeutics, down from -$0.04 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.02 in Q2 2025, with the low at -$3.56 in Q2 2022.
  • Average EPS (Basic) over 5 years is -$0.92, with a median of -$0.49 recorded in 2024.
  • The sharpest move saw EPS (Basic) tumbled 1324.0% in 2022, then soared 104.44% in 2025.
  • Over 5 years, EPS (Basic) stood at -$0.28 in 2021, then plummeted by 742.86% to -$2.36 in 2022, then surged by 70.34% to -$0.7 in 2023, then soared by 30.0% to -$0.49 in 2024, then soared by 85.01% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.07, -$0.04, and $0.02 for Q4 2025, Q3 2025, and Q2 2025 respectively.